Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...

Erectile dysfunction affects over 40% of men over 40, yet our understanding of the condition remains limited. Research on this issue has mostly relied on real organs, making it difficult to study the ...

Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...

Humacyte's stock struggles despite FDA approval for Symvess, with financial concerns and slow adoption impacting future ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Researchers at Saratov State University and their colleagues have developed an innovative approach to improving the ...

Alma Lasers, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, announced today ...

PNC Financial Services Group Inc. trimmed its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 4.1% during ...

A research team has successfully developed an innovative platform for diabetes treatment using bioink derived from pancreatic ...

DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable ...

– Positive responses from surgeons and trauma centers to initial sales and marketing outreach – - 21 hospitals have already initiated the Value Analysis Committee (VAC) approval process ...